Resectable Pancreatic Cancer
29
6
9
8
Key Insights
Highlights
Success Rate
62% trial completion
Clinical Risk Assessment
Based on trial outcomes
High Risk
Score: 59/100
17.2%
5 terminated out of 29 trials
61.5%
-25.0% vs benchmark
3%
1 trials in Phase 3/4
63%
5 of 8 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 8 completed trials
Clinical Trials (29)
Pre-operative Treatment for Patients With Untreated Pancreatic Cancer
A Study of NovoTTF-200T(P) in Combination With Gemcitabine and Nab-Paclitaxel for Resectable Pancreatic Adenocarcinoma
Implementing ctDNA and Circular DNA in Patients With Localized Pancreatic Cancer
GATA6 Expression as a Predictor of Response to Peri-Operative Chemotherapy in Resectable Pancreatic Adenocarcinoma
Surgery Impact on Circulating Tumor DNA in Pancreatic Cancer
Testing the Combination of Two Approved Chemotherapy Drugs and Radiation Prior to Surgery in Localized Pancreatic Cancer
Ivosidenib + mFOLFIRINOX in Patients With Resectable Pancreatic Adenocarcinoma
Predictive Risk Factors for Pancreatic Fistula After Pancreaticoduodenectomy
Comparative Study Between Immediate Surgery Versus Neoadjuvant Chemotherapy for Management of Resectable Pancreatic Cancer
Carbon Ions Radiation Therapy for Resectable or Borderline Resectable Pancreas Adenocarcinoma
A Trial of NIS793 With FOLFIRINOX in Pancreatic Cancer
NeoFOL-R Trial (Perioperative Versus Adjuvnat FOLFIRINOX in Resectable Pancreatic Cancer)
Intraoperative Radiation Therapy for Resectable Pancreatic Cancer
A Retrospective Study for Nimotuzumab Plus Postoperative Adjuvant Chemotherapy for Resectable Pancreatic Cancer
Irinotecan Liposome for Resectable Pancreatic Cancer With or Without Addebelizumab
Efficacy of Doxycycline on Metakaryote Cell Death in Patients With Resectable Pancreatic Cancer
Neoadjuvant Plus Adjuvant or Only Adjuvant Nab- Paclitaxel Plus Gemcitabine for Resectable Pancreatic Cancer
Phase II Study on Sequential AG and FOLFIRINOX as Neoadjuvant Therapy in Patients With Resectable Pancreatic Cancer
ARTEMIS: Study of Patients With Early Stage Pancreatic Cancer Who Have Undergone Genetic Testing
Personalized Neoantigen Vaccine in Pancreatic Cancer Patients Following Surgical Resection and Adjuvant Chemotherapy